Published in Healthcare Mergers, Acquisitions and Ventures Week, May 1st, 2004
Global Life Science Ventures (Germany, Switzerland, U.K) and AXA Private Equity Venture Funds from France also participated in the investment consortium.
Agendia is a pharmacogenomics company founded recently by scientists from the Netherlands Cancer Institute (NKI) in Amsterdam who have developed the first microarray-based diagnostic test to predict the aggressiveness of breast cancer tumors based on the activity of key genes. The important discovery of a predictive breast cancer profile and its validation in an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week